Radiation therapy for patients with relapsed or refractory mantle cell lymphoma undergoing CD19-targeted chimeric antigen receptor T-cell therapy

Hematol Oncol. 2024 Jan;42(1):e3221. doi: 10.1002/hon.3221. Epub 2023 Sep 7.

Authors

Hazim S Ababneh¹, Matthew J Frigault², Chirayu G Patel¹

Affiliations

¹ Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.
² Division of Hematology & Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 37679941
DOI: 10.1002/hon.3221

No abstract available

Publication types

Letter

MeSH terms

Adult
Antigens, CD19
Cell- and Tissue-Based Therapy
Humans
Immunotherapy, Adoptive / adverse effects
Lymphoma, Mantle-Cell* / etiology
Lymphoma, Mantle-Cell* / radiotherapy
Receptors, Antigen, T-Cell / genetics
Receptors, Chimeric Antigen*

Substances

Receptors, Chimeric Antigen
Receptors, Antigen, T-Cell
Antigens, CD19